(Q33444662)

26 July 2017

Test validity of periodic liver function tests in a population of Japanese male bank employees (English)

1 reference

26 July 2017

Yano E

1

1 reference

26 July 2017

Tagawa K

series ordinal

2

1 reference

26 July 2017

Yamaoka K

series ordinal

3

1 reference

26 July 2017

Mori M

series ordinal

4

1 reference

26 July 2017

1 September 2001

1 reference

Journal of Clinical Epidemiology

26 July 2017

1 reference

26 July 2017

54

1 reference

26 July 2017

9

1 reference

26 July 2017

945-951

1 reference

Therapy of hepatitis C: overview

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

The accuracy of ultrasound in the detection of fatty infiltration of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Validation of screening procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Hepatitis C in asymptomatic blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Serum-gamma-glutamyltransferase in screening and continuous control of heavy drinking in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Serum activity of gamma-glutamyltranspeptidase (GGT) in relation to estimated alcohol consumption and questionnaires in alcohol dependence syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Mean cell volume and gamma-glutamyl-transpeptidase as markers of drinking in working men

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Gamma glutamyl transpeptidase and mean corpuscular volume: their usefulness in the assessment of in-patient alcoholics

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

A community screening test for high alcohol consumption using biochemical and haematological measures

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

Utility and evaluation of biochemical markers of alcohol consumption

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900355-9

7 January 2021

10.1016/S0895-4356(01)00355-9

Identifiers

DOI

1 reference

26 July 2017

1 reference